Insider Selling: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) CEO Sells 12,145 Shares of Stock

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) CEO Scott Braunstein sold 12,145 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $1.13, for a total value of $13,723.85. Following the completion of the sale, the chief executive officer now directly owns 298,667 shares of the company’s stock, valued at $337,493.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS traded up $0.01 during trading on Wednesday, hitting $1.16. 405,828 shares of the company were exchanged, compared to its average volume of 1,273,024. The firm’s fifty day moving average price is $1.37 and its 200 day moving average price is $4.75. The company has a debt-to-equity ratio of 5.68, a current ratio of 3.07 and a quick ratio of 2.93. The company has a market cap of $63.72 million, a price-to-earnings ratio of -0.44 and a beta of 1.13. Marinus Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.68). Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. The company had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $8.61 million. On average, sell-side analysts expect that Marinus Pharmaceuticals, Inc. will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in Marinus Pharmaceuticals during the second quarter worth $34,000. Values First Advisors Inc. increased its position in shares of Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 52,257 shares in the last quarter. Hussman Strategic Advisors Inc. grew its stake in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 10,500 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Marinus Pharmaceuticals during the 1st quarter valued at about $384,000. Finally, Trexquant Investment LP purchased a new position in Marinus Pharmaceuticals during the 4th quarter valued at about $553,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MRNS shares. Robert W. Baird reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Royal Bank of Canada restated a “sector perform” rating and issued a $3.00 price objective (down from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Finally, Truist Financial restated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.79.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.